{"transactions":[{"id":987305,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72525,"kind":"person","name":"Murali Ramachandran","position":1,"cik":"0001870016","reported_name":"Murali Ramachandran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Research and Development"}}],"security":"COMMON STOCK","published_at":"2025-11-26T18:50:34.000Z","date":"2025-10-08","kind":"grant","planned":false,"acquired":true,"shares":152672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 152,672 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (1) 142,191 shares of common stock and (2) 157,338 RSUs which remain subject to vesting."}],"balance_after":299529,"source":{"system":"sec-edgar","filing":"0001493152-25-025224","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870016/000149315225025224/ownership.xml","form_type":"4"}},{"id":1249897,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72525,"kind":"person","name":"Murali Ramachandran","position":1,"cik":"0001870016","reported_name":"Murali Ramachandran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Research and Development"}}],"security":"COMMON STOCK","published_at":"2025-02-24T18:52:11.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 14,000 restricted stock units (\"RSUs\") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of (1) 137,724 shares of common stock and (2) 9,333 RSUs which remain subject to vesting."}],"balance_after":147057,"source":{"system":"sec-edgar","filing":"0001493152-25-008106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870016/000149315225008106/ownership.xml","form_type":"4"}},{"id":1352874,"issuer":{"id":8244,"kind":"organization","name":"Kairos Pharma, LTD."},"owners":[{"id":72525,"kind":"person","name":"Murali Ramachandran","position":1,"cik":"0001870016","reported_name":"Murali Ramachandran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP of Research and Development"}}],"security":"COMMON STOCK","published_at":"2024-11-25T20:30:12.000Z","date":"2024-11-25","kind":"purchase","planned":false,"acquired":true,"shares":200,"price":1.59,"value":318.0,"ownership":{"direct":true},"balance_after":133057,"source":{"system":"sec-edgar","filing":"0001493152-24-047695","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870016/000149315224047695/ownership.xml","form_type":"4"}}]}